Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

CV Risk After Acute COVID-19 Not So High as Feared: Registry

News Daily News

CV Risk After Acute COVID-19 Not So High as Feared: Registry

January 06, 2023

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

News Daily News

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

October 28, 2022

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

News Daily News

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

October 26, 2022

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

News Daily News

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

September 16, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

VTE Risk Higher With COVID-19 Than With Flu

News Daily News

VTE Risk Higher With COVID-19 Than With Flu

August 18, 2022

ACC Releases Guidance on CV Issues With COVID-19

News Daily News

ACC Releases Guidance on CV Issues With COVID-19

March 16, 2022

Consider COVID-19 History in Pre-op CV Screening, Doctors Say

News Daily News

Consider COVID-19 History in Pre-op CV Screening, Doctors Say

January 14, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for October Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 1

October 04, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

News Daily News

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

June 14, 2021

COVID-19: TCTMD’s Daily Dispatch for June Week 1

News Daily News

COVID-19: TCTMD’s Daily Dispatch for June Week 1

June 01, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

May 2021 News Roundup

News Opinion CV Team Dispatch

May 2021 News Roundup

May 01, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.